- Home
- EWTX vs RDFN Comparison
EWTX vs RDFN Comparison
Compare EWTX & RDFN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWTX
- RDFN
- Stock Information
- Founded
- EWTX 2017
- RDFN 2002
- Country
- EWTX United States
- RDFN United States
- Employees
- EWTX N/A
- RDFN N/A
- Industry
- EWTX Biotechnology: Pharmaceutical Preparations
- RDFN Real Estate
- Sector
- EWTX Health Care
- RDFN Finance
- Exchange
- EWTX Nasdaq
- RDFN Nasdaq
- Market Cap
- EWTX 1.2B
- RDFN 1.3B
- IPO Year
- EWTX 2021
- RDFN 2017
- Fundamental
- Price
- EWTX $14.30
- RDFN $11.24
- Analyst Decision
- EWTX Buy
- RDFN Hold
- Analyst Count
- EWTX 8
- RDFN 11
- Target Price
- EWTX $39.63
- RDFN $10.85
- AVG Volume (30 Days)
- EWTX 932.9K
- RDFN 6.4M
- Earning Date
- EWTX 08-07-2025
- RDFN 08-05-2025
- Dividend Yield
- EWTX N/A
- RDFN N/A
- EPS Growth
- EWTX N/A
- RDFN N/A
- EPS
- EWTX N/A
- RDFN N/A
- Revenue
- EWTX N/A
- RDFN $1,038,527,000.00
- Revenue This Year
- EWTX N/A
- RDFN N/A
- Revenue Next Year
- EWTX N/A
- RDFN $5.32
- P/E Ratio
- EWTX N/A
- RDFN N/A
- Revenue Growth
- EWTX N/A
- RDFN 5.11
- 52 Week Low
- EWTX $10.60
- RDFN $5.49
- 52 Week High
- EWTX $38.12
- RDFN $15.29
- Technical
- Relative Strength Index (RSI)
- EWTX 41.90
- RDFN 64.56
- Support Level
- EWTX $14.87
- RDFN $10.29
- Resistance Level
- EWTX $15.68
- RDFN $11.09
- Average True Range (ATR)
- EWTX 0.67
- RDFN 0.50
- MACD
- EWTX -0.02
- RDFN 0.06
- Stochastic Oscillator
- EWTX 15.25
- RDFN 91.98
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
About RDFN Redfin Corporation
Redfin Corp is a residential real estate broker. It pairs its agents with the technology to create a service that is faster and costs less. The company meets customers through a listings-search website and mobile application. The company uses the same combination of technology and local service to originate mortgage loans and offer title and settlement services. It has five operating segments real estate services, rentals, mortgage, title, and monetization. The company generates the majority of its revenue from Real estate services.